Immune-mediated diseases of the central nervous system show wide variability both symptomatically and with respect to underlying pathophysiology. Recognizing aberrant immunologic activity as the cause of neurologic dysfunction requires establishing as precise a neuroanatomic and functional phenotype as possible, and a diagnostic and therapeutic strategy that stabilizes the patient, excludes broad categories of disease via rapidly available diagnostic assays, and maintains a broad differential diagnosis that includes immune-mediated conditions. This process is aided by recognizing the appropriate clinical circumstances under which immune-mediated disease should be suspected, and how to differentiate these conditions from other causes of similar neurologic dysfunction.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.pcl.2016.08.005 | DOI Listing |
JMIR Res Protoc
January 2025
Department of Orthopaedic Surgery, National University Hospital, National University Health System, Singapore, Singapore.
Background: Metastatic spine tumor surgery (MSTS) is often complex and extensive leading to significant blood loss. Allogeneic blood transfusion (ABT) is the mainstay of blood replenishment but with immune-mediated postoperative complications. Alternative blood management techniques (salvaged blood transfusion [SBT]) allow us to overcome such complications.
View Article and Find Full Text PDFDrugs Real World Outcomes
January 2025
Biogen IDEC, Clinical Research, Biosimilars, Maidenhead, UK.
Acta Neuropathol Commun
January 2025
Department of Neurology, Mayo Clinic, Rochester, MN, 55905, USA.
Rippling Muscle Disease (RMD) is a rare skeletal myopathy characterized by abnormal muscular excitability manifesting with wave-like muscle contractions and percussion-induced muscle mounding. Hereditary RMD is associated with caveolin-3 or cavin-1 mutations. Recently, we identified cavin 4 autoantibodies as a biomarker of immune-mediated RMD (iRMD), though the underlying disease-mechanisms remain poorly understood.
View Article and Find Full Text PDFImmunopharmacol Immunotoxicol
January 2025
Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University School of Medicine, 310003 Hangzhou, China.
Background: The incidence of hepatic immune-related adverse events has increased with the wide use of immune checkpoint inhibitors, some immune-mediated hepatotoxicity cases are severe and lack of clinical recommendations.
Objective: This study aimed to evaluate the efficacy of artificial liver support systems (ALSS) in the treatment of immune-mediated hepatotoxicity.
Methods: This retrospective case series included six patients with grade 4 hepatotoxicity with high bilirubin induced by immune checkpoint inhibitors treated between January 1, 2019, to December 31, 2021.
Circ Res
January 2025
Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Germany (A.C., C.B.).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!